Nektar Therapeutics Inc. could help its bottom line — and move closer toward paying off debt — by doing almost nothing Monday and Tuesday.
San Francisco-based Nektar (NASDAQ: NKTR) is in line for royalty payments if the Food and Drug Administration on Monday approves an acute migraine drug from MAP Pharmaceuticals Inc. (NASDAQ: MAP) and partner Allergan Inc. It would collect more royalties if an anemia drug from Affymax Inc. (NASDAQ: AFFY) and Takeda Pharmaceutical Co. Ltd. is approved Tuesday.
Both drugs use know-how developed by and licensed from Nektar.
Showing posts with label Affymax. Show all posts
Showing posts with label Affymax. Show all posts
Sunday, March 25, 2012
Tuesday, March 6, 2012
Biotech's battle: Rebuild industry for next wave of drugs
Maybe it’s overdramatizing to say it feels like we’re passing through history, but as a number of Bay Area biopharma companies approach the cusp of drug approvals, it feels like we may not pass this way again.
It’s something to consider as the state’s biomedical industry players meet this week for the CalBio 2012 conference in San Francisco.
Maybe it’s my limited experience, but the sheer volume of drugs from Bay Area companies that are in front of the FDA in early 2012 seems unprecedented. After watching capital dry up for four years, just getting to this point seems a victory for some companies.
But for today's small life sciences companies to deliver big-time drugs in the coming years will take a new model for funding.
It’s something to consider as the state’s biomedical industry players meet this week for the CalBio 2012 conference in San Francisco.
Maybe it’s my limited experience, but the sheer volume of drugs from Bay Area companies that are in front of the FDA in early 2012 seems unprecedented. After watching capital dry up for four years, just getting to this point seems a victory for some companies.
But for today's small life sciences companies to deliver big-time drugs in the coming years will take a new model for funding.
Wednesday, February 29, 2012
Nektar to apply royalty windfall toward paying off debt
Nektar Therapeutics Inc. will use its $124 million windfall from the sale of its royalty interest in two drugs to help pay off a $215 million note due in September.
In a Securities and Exchange Commission filing Wednesday, the San Francisco-based drug developer (NASDAQ: NKTR) said it also is pursuing other “non-dilutive financing alternatives,” including the sale of other royalty interests, to pay off the convertible subordinated note.
In a Securities and Exchange Commission filing Wednesday, the San Francisco-based drug developer (NASDAQ: NKTR) said it also is pursuing other “non-dilutive financing alternatives,” including the sale of other royalty interests, to pay off the convertible subordinated note.
Monday, February 27, 2012
Affymax nabs $5M milestone payment from Takeda
Affymax Inc. said Monday it is expected to received a $5 million development milestone payment from Takeda Pharmaceutical Co.
The Palo Alto-based biopharmaceutical company (NASDAQ:AFFY) said the payment comes as a result of a global agreement between the two companies to develop and commercialize peginesatide — a drug aimed at treating anemia in dialysis patients with chronic kidney disease. It is being co-developed by the two companies.
The payment comes as a result of the European Medicines Agency accepting the Marketing Authorization Application for peginesatide.
The Palo Alto-based biopharmaceutical company (NASDAQ:AFFY) said the payment comes as a result of a global agreement between the two companies to develop and commercialize peginesatide — a drug aimed at treating anemia in dialysis patients with chronic kidney disease. It is being co-developed by the two companies.
The payment comes as a result of the European Medicines Agency accepting the Marketing Authorization Application for peginesatide.
Friday, January 13, 2012
Scenes, thoughts from the J.P. Morgan Healthcare Conference
If the Occupy Wall Street folks wanted to shut down biotech’s biggest wheeling-and-dealing session, the 30th annual J.P. Morgan Healthcare Conference, couldn’t they just contact the San Francisco fire marshal?
The Occupy movement supposedly was the reason J.P. Morgan asked the Westin St. Francis for additional security for the conference this week. Badge-checkers were at their usual stations inside the hotel but also were moved outside of the hotel, creating more logjams than usual on the sidewalk along Union Street.
Folks staying at the hotel had to show their room keys, so the security crush significantly cut down “clock tower” meetings in the hotel’s lobby. Coupled with the unusually good January weather, Union Square became the preferred chat-up locale, to the point that the park was overrun by posses of (mostly) men in black suits.
All in all, the mood seemed less dreamy, more serious. Even last year, life sciences companies still in shock from the financial crisis seemed like zombies: “Must focus portfolio … arrrrrgh … Be virtual … ugh.” They walked the talk, but they didn’t really seem to mean it. This year, the companies indeed were focused, their milestones tangible.
The Occupy movement supposedly was the reason J.P. Morgan asked the Westin St. Francis for additional security for the conference this week. Badge-checkers were at their usual stations inside the hotel but also were moved outside of the hotel, creating more logjams than usual on the sidewalk along Union Street.
Folks staying at the hotel had to show their room keys, so the security crush significantly cut down “clock tower” meetings in the hotel’s lobby. Coupled with the unusually good January weather, Union Square became the preferred chat-up locale, to the point that the park was overrun by posses of (mostly) men in black suits.
All in all, the mood seemed less dreamy, more serious. Even last year, life sciences companies still in shock from the financial crisis seemed like zombies: “Must focus portfolio … arrrrrgh … Be virtual … ugh.” They walked the talk, but they didn’t really seem to mean it. This year, the companies indeed were focused, their milestones tangible.
Friday, December 30, 2011
Industry view: Changes to business model come slowly to biotech
Entering the fifth year of a funding crisis, biotech’s business model is changing.
Slowly.
New sources of early-stage cash are stepping into the void left by fleeing venture capitalists. But whether those relatively small investments — or corporate venture capital, or grants from disease-specific foundations — are enough to build sustainable companies is an open question.
(San Francisco Business Times subscription required.)
Slowly.
New sources of early-stage cash are stepping into the void left by fleeing venture capitalists. But whether those relatively small investments — or corporate venture capital, or grants from disease-specific foundations — are enough to build sustainable companies is an open question.
(San Francisco Business Times subscription required.)
Wednesday, December 7, 2011
FDA panel backs Affymax anemia drug for dialysis patients
A federal advisory panel Wednesday approved Affymax Inc.’s once-a-month anemia drug for kidney dialysis patients.
The 17-member Food and Drug Administration panel of outside experts recommended that the agency approve peginesatide from Palo Alto-based Affymax (NASDAQ: AFFY) and partner Takeda Pharmaceuticals. Two Phase III studies showed that the drug is safe and effective for dialysis patients, but two other late-stage studies found that peginesatide could cause heart problems in kidney patients who weren’t yet on dialysis.
The FDA often follows an advisory panel’s recommendation but isn’t required to do so. The FDA is expected to approve or reject peganesatide by March 27.
The 17-member Food and Drug Administration panel of outside experts recommended that the agency approve peginesatide from Palo Alto-based Affymax (NASDAQ: AFFY) and partner Takeda Pharmaceuticals. Two Phase III studies showed that the drug is safe and effective for dialysis patients, but two other late-stage studies found that peginesatide could cause heart problems in kidney patients who weren’t yet on dialysis.
The FDA often follows an advisory panel’s recommendation but isn’t required to do so. The FDA is expected to approve or reject peganesatide by March 27.
Friday, October 21, 2011
Hedge fund BVF takes 6.1% stake in Affymax
Biotechnology Value Fund has accumulated 6.1 percent of Affymax Inc., the hedge fund said in a filing Friday with the Securities and Exchange Commission.
BVF, with offices in Chicago and San Francisco, said it controls 2.15 million shares of Palo Alto-based Affymax’s (NASDAQ: AFFY) roughly 35.5 million shares. BVF had not previously stated a position in the anemia drug developer.
BVF, with offices in Chicago and San Francisco, said it controls 2.15 million shares of Palo Alto-based Affymax’s (NASDAQ: AFFY) roughly 35.5 million shares. BVF had not previously stated a position in the anemia drug developer.
Friday, July 15, 2011
Affymax preps for dialysis drug debut
After two decades, a name change for its lead product and damaging late-stage trial data a year ago, Affymax Inc. ’s first drug is ready for show time.
The Palo Alto company’s drug, called Peginesatide, could break Amgen Inc.’s virtual monopoly on treating anemia in kidney dialysis patients. In May, Affymax submitted its application for Food and Drug Administration approval of the drug.
In early or mid-August, the agency will say whether it accepts the 800,000-page application and set a target approval date, likely to be in early 2012.
The Palo Alto company’s drug, called Peginesatide, could break Amgen Inc.’s virtual monopoly on treating anemia in kidney dialysis patients. In May, Affymax submitted its application for Food and Drug Administration approval of the drug.
In early or mid-August, the agency will say whether it accepts the 800,000-page application and set a target approval date, likely to be in early 2012.
Monday, May 9, 2011
Affymax Q1 loss widens to $9.6 million
Affymax Inc. on Monday reported a first quarter loss of $9.6 million, widened from a loss of $7.9 million in the same period last year.
Palo Alto-based Affymax (NASDAQ:AFFY) had revenue of $16.7 million, about half the year-ago quarter's $34.7 million.
Palo Alto-based Affymax (NASDAQ:AFFY) had revenue of $16.7 million, about half the year-ago quarter's $34.7 million.
Friday, May 6, 2011
Mohr Davidow hires Affymax CFO as first COO
Venture firm Mohr Davidow in Menlo Park created the job of chief operating officer and tapped Paul Cleveland to fill it.
Cleveland, who was chief financial officer at Affymax Inc. from January 2006 until February 2011, also becomes a general partner at Mohr Davidow.
As COO, Cleveland will handle all finance, operations and administration work at the firm.
Cleveland, who was chief financial officer at Affymax Inc. from January 2006 until February 2011, also becomes a general partner at Mohr Davidow.
As COO, Cleveland will handle all finance, operations and administration work at the firm.
Friday, March 18, 2011
Affymax in $50 million stock sale
Affymax Inc. is planning to raise about $50 million in a sale of its common stock, the company said Friday.
Palo Alto-based Affymax (NASDAQ:AFFY) plans to sell about 8.5 million shares to the public at $5.90 per share.
Palo Alto-based Affymax (NASDAQ:AFFY) plans to sell about 8.5 million shares to the public at $5.90 per share.
Thursday, March 10, 2011
Affymax trims loss in 2010
Affymax Inc. on Thursday reported a 2010 fiscal year loss of $14.1 million, down from a loss in the prior year of $76.5 million.
Palo Alto-based Affymax (NASDAQ:AFFY) reported $112.5 million in revenue during the year, down from 2009's $114.9 million.
Palo Alto-based Affymax (NASDAQ:AFFY) reported $112.5 million in revenue during the year, down from 2009's $114.9 million.
Thursday, January 6, 2011
Subscribe to:
Posts (Atom)





